Citigroup Inc Cor Medix Inc. Transaction History

Citigroup Inc

$190 Billion
Q1 2025

A detailed history of Citigroup Inc transactions in Cor Medix Inc. stock. As of the latest transaction made, Citigroup Inc holds 57,624 shares of CRMD stock, worth $730,672. This represents 0.0% of its overall portfolio holdings.

Number of Shares

57,624

Previous 63,369 9.07%

Holding current value

$730,672

Previous $513,000 30.99%

% of portfolio

0.0%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2025 May 12, 2025	SELL	$6.16 - $12.57 $35,389 - $72,214	-5,745 Reduced 9.07%	57,624 $354,000
Q4 2024 Feb 12, 2025	BUY	$8.1 - $13.59 $190,058 - $318,875	23,464 Added 58.8%	63,369 $513,000
Q3 2024 Nov 12, 2024	BUY	$3.64 - $8.23 $100,755 - $227,806	27,680 Added 226.42%	39,905 $322,000
Q2 2024 Aug 12, 2024	BUY	$4.08 - $6.39 $12,158 - $19,042	2,980 Added 32.23%	12,225 $52,000
Q1 2024 May 10, 2024	BUY	$2.94 - $4.24 $4,468 - $6,444	1,520 Added 19.68%	9,245 $39,000
Q4 2023 Feb 09, 2024	BUY	$3.0 - $4.01 $23,106 - $30,885	7,702 Added 33486.96%	7,725 $29,000
Q3 2023 Nov 09, 2023	SELL	$3.6 - $4.46 $60,998 - $75,570	-16,944 Reduced 99.86%	23 $0
Q2 2023 Aug 10, 2023	BUY	$3.94 - $5.8 $66,849 - $98,408	16,967 New	16,967 $67,000
Q2 2022 Aug 10, 2022	SELL	$2.73 - $5.61 $3,382 - $6,950	-1,239 Reduced 76.25%	386 $2,000
Q1 2022 May 12, 2022	SELL	$3.83 - $6.24 $30,712 - $50,038	-8,019 Reduced 83.15%	1,625 $9,000
Q4 2021 Feb 10, 2022	BUY	$4.47 - $5.56 $23,811 - $29,618	5,327 Added 123.4%	9,644 $44,000
Q3 2021 Nov 10, 2021	BUY	$4.46 - $7.11 $19,253 - $30,693	4,317 New	4,317 $20,000

Others Institutions Holding CRMD

# of Institutions

148

Shares Held

22.7M

Call Options Held

475K

Put Options Held

777K

View Full List

About CorMedix Inc.

Ticker CRMD
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 41,208,200
Market Cap $523M
Description
CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States and internationally. Its lead product candidate is DefenCath/Neutrolin, a novel anti-infective solution for the reduction and prevention of cathet...

More about CRMD

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Citigroup Inc, based on Form 13F filings with the SEC.

News

Stay updated on Citigroup Inc with notifications on news.

Account